Regeneron reaches patent deal with Celltrion over Eylea biosimilar https://lnkd.in/d4HBNKcw Celltrion can sell a biosimilar version of Regeneron’s Eylea in the US at the end of 2026, following a patent deal between the two companies that also clears the path for more competition against the [...]

PNBN Trending News: Regeneron reaches patent deal with Celltrion over Eylea biosimilar https://lnkd.in/g_vSxMmw Celltrion can sell a biosimilar version of Regeneron’s Eylea in the US at the end of 2026, following a patent deal between the two companies that also clears the path for more competition against the [...]

📈 STOX the Money™ Cutting Through the Noise. Daily. 💊 SC Backs Natco in Roche Patent Fight In a major boost for patients, the Supreme Court dismissed Roche’s appeal, allowing Natco Pharma to sell its generic of Risdiplam (SMA drug). 📉 Roche’s Evrysdi: ₹6,30,000/bottle 💊 Natco’s version: ₹15,900 — 97% cheaper 📊 Market View: ✅ Bullish cue for Natco Pharma ⚖️ Reinforces public health over patent monopoly 💡 May trigger fresh debate on pharma IP & pricing 💬 Access wins over monopoly, justice for patients, opportunity for innovators.

📈 STOX the Money™ Cutting Through the Noise. Daily. 💊 SC Backs Natco in Roche Patent Fight In a major boost for patients, the Supreme Court dismissed Roche’s appeal, allowing Natco Pharma to sell its generic of Risdiplam (SMA drug). 📉 Roche’s Evrysdi: ₹6,30,000/bottle 💊 Natco’s version: ₹15,900 — 97% cheaper 📊 Market View: ✅ Bullish cue for Natco Pharma ⚖️ Reinforces public health over patent monopoly 💡 May trigger fresh debate on pharma IP & pricing 💬 Access wins over monopoly, justice for patients, opportunity for innovators.

📣 We are pleased to announce that we have entered into a Business Partnership Agreement (“the Agreement”) with Axcelead Drug Discovery Partners, Inc. ("Axcelead DDP”) in the Integrated Drug Discovery (IDD) business. 🤝 🎉 Through this collaboration, both companies aim to enhance their contribution to drug discovery by leveraging each other's respective strengths. 👍 💪 ✔️ For more details, please refer to the press release on our website! https://lnkd.in/gfybUtge #Axcelead #Chiome #IDD #Antibody

Antibody-Oligonucleotide Conjugates (AOCs) have the potential to transform therapies. However, the development of AOCs is far from straightforward. While AOCs & ADCs share structural similarities, their development processes differ significantly due to the complexity of oligo payloads in AOCs. These differences present distinct technical and analytical challenges that developers must address. In our latest article in Outsourced Pharma, our AOC experts, Jeffrey C. Mocny, Ph.D. & Stephen Verespy discuss the scientific ingenuity necessary to develop these complex molecules and the regulatory considerations to ensure a smooth pathway to approval. Access the article to get a better understanding of the intricate chemistry and technical expertise required to successfully develop and manufacture these complex molecules: https://lnkd.in/g2aCNXFG #AOCs #Bioconjugates #CDMO #CRO #DrugDevelopment

✅ It’s official — we’re launching the 𝗖𝗼𝘃𝗮𝗹𝗲𝗻𝘁 𝗦𝘂𝗶𝘁𝗲, a powerful extension of our physics-based platform for 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗰𝗼𝘃𝗮𝗹𝗲𝗻𝘁 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿 (TCI) design. Catch a glimpse in this teaser, and 𝗷𝗼𝗶𝗻 𝗼𝘂𝗿 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 to see how SilcsBio is advancing covalent drug discovery. 👉 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗵𝗲𝗿𝗲: https://lnkd.in/eYD9Aibi #DrugDesign #CompChem #Covalent #Warheads #SILCS #SilcsBio

🚀 Turning plans into progress at Biosimax This past quarter, we’ve made significant strides in building a robust platform for biosimilar development and market access... ✅ Cell line license and purchase agreement secured ✅ Engagement with the MHRA underway ✅ European market access arrangements in place ✅ Technical partnerships established ✅ Ongoing support from NHS collaborators Each milestone brings us closer to delivering high-quality, affordable biologics to patients across Europe and beyond 🌍. More to come soon on our partnership with Orfenix and our European strategy — watch this space. #Biosimilars #Biotech #MHRA #MarketAccess #LifeSciences #UKBiotech #HealthInnovation #Biosimax

Welcome to the Queensland State Pavilion, where TRI is exhibiting during this week's AusBiotech International Conference in Melbourne. Industry Development and Tenancy Manager Glenda Colburn (pictured right, with Director of Corporate Affairs and Marketing Shari Armistead GAICD FIML) is sharing details of TRI's translational ecosystem and our pre-clinical, clinical, and cGMP biomedical manufacturing facilities. Our facilities include ENTRI, a purpose-designed cGMP manufacturing facility under construction and due to open in early 2026, with support from the Queensland Government and TRI. Read more about ENTRI: https://lnkd.in/gdERiN6M Read more about AusBiotech 2025: https://ausbiotechic.com/ Maher Gandhi

Esperion has reached a key patent settlement with Dr. Reddy's Laboratories, securing market exclusivity for #NEXLETOL® and #NEXLIZET® in the U.S. until 2040. #Esperion #DrReddys #PharmaNews #CardiovascularHealth #DrugInnovation #PatentProtection #LifeSciences #Biopharma #HealthcareInnovation https://lnkd.in/dfNc6vxv